Hanyang Med Rev.  2016 May;36(2):125-130. 10.7599/hmr.2016.36.2.125.

Intratympanic Steroid Injection in Tinnitus Management

Affiliations
  • 1Department of Otorhinolaryngology-Head and Neck Surgery, Eulji University School of Medicine, Eulji Medical Center, Seoul, Korea. eardoc11@naver.com

Abstract

Intratympanic (IT) steroid injection has been used increasingly in various inner ear diseases instead of systemic steroid, because of the higher concentration of the drug into the target organ and the lower risk of the systemic side effect. Although there were several trials applying IT steroid injection on tinnitus, most of them failed to demonstrate its therapeutic effect more than controls. However, a study has shown a meaningful outcome when the therapeutic target is limited to acute tinnitus developed within 3 months. Although IT steroid injection treatment in tinnitus requires more evidence, when the therapeutic target is limited to the acute phase, IT steroid injection could be a treatment option for tinnitus. Early intervention, asymmetric hearing loss and unilateral tinnitus seem to be favorable factors for outcome of IT steroid injection.

Keyword

Steroid; Intratympanic; Tinnitus; Sudden Hearing Loss

MeSH Terms

Early Intervention (Education)
Hearing Loss
Hearing Loss, Sudden
Labyrinth Diseases
Tinnitus*

Cited by  1 articles

Tinnitus: Overview
Chul Won Park
Hanyang Med Rev. 2016;36(2):79-80.    doi: 10.7599/hmr.2016.36.2.79.


Reference

1. Sakata E, Kitago Y, Murata Y, Teramoto K. Treatment of Meniere's disease. Middle ear infusion with lidocaine and steroid solution. Auris Nasus Larynx. 1986; 13:79–89.
2. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol. 2001; 22:18–23.
Article
3. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999; 109:1–17.
Article
4. Pitovski DZ, Drescher MJ, Drescher DG. Glucocorticoid receptors in the mammalian inner ear: RU 28362 binding sites. Hear Res. 1994; 77:216–220.
Article
5. Rarey KE, Lohuis PJ, ten Cate WJ. Response of the stria vascularis to corticosteroids. Laryngoscope. 1991; 101:1081–1084.
Article
6. Trune DR, Kempton JB, Gross ND. Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hear Res. 2006; 212:22–32.
Article
7. Rauch SD, Halpin CF, Antonelli PJ, Babu S, Carey JP, Gantz BJ, et al. Oral vs Intratympanic Corticosteroid Therapy for Idiopathic Sudden SensorineuralHearing Loss. JAMA. 2011; 305:2071–2079.
Article
8. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012; 146:3 Suppl. S1–35.
Article
9. Seggas I, Koltsidopoulos P, Bibas A, Tzonou A, Sismanis A. Intratympanic steroid therapy for sudden hearing loss: a review of the literature. Otol Neurotol. 2011; 32:29–35.
10. Sakata E, Itoh A, Itoh Y. Treatment of cochlear-tinnitus with dexamethasone infusion into the tympanic cavity. Int Tinnitus J. 1996; 2:129–135.
11. Cesarani A, Capobianco S, Soi D, Giuliano DA, Alpini D. Intratympanic dexamethasone treatment for control of subjective idiopathic tinnitus: our clinical experience. Int Tinnitus J. 2002; 8:111–114.
12. Choi SJ, Lee JB, Lim HJ, In SM, Kim JY, Bae KH, et al. Intratympanic dexamethasone injection for refractory tinnitus: Prospective placebo-controlled study. Laryngoscope. 2013; 123:2817–2822.
Article
13. Araújo MF, Oliveira CA, Bahmad FM Jr. Intratympanic dexamethasone injections as a treatment for severe, disabling tinnitus: does it work? Arch Otolaryngol Head Neck Surg. 2005; 131:113–117.
Article
14. Topak M, Sahin-Yilmaz A, Ozdoganoglu T, Yilmaz HB, Ozbay M, Kulek-ci M. Intratympanic methylprednisolone injections for subjective tinnitus. J Laryngol Otol. 2009; 123:1221–1225.
Article
15. She W, Dai Y, Du X, Chen F, Ding X, Cui X. Treatment of subjective tinnitus: a comparative clinical study of intratympanic steroid injection vs. oral carbamazepine. Med Sci Monit. 2009; 15:PI35–PI39.
16. Shim HJ, Song SJ, Choi AY, Hyung Lee R, Yoon SW. Comparison of various treatment modalities for acute tinnitus. Laryngoscope. 2011; 121:2619–2625.
Article
17. Nyenhuis N, Zastrutzki S, Weise C, Jager B, Kroner-Herwig B. The efficacy of minimal contact interventions for acute tinnitus: a randomised controlled study. Cogn Behav Ther. 2013; 42:127–138.
Article
18. Tunkel DE, Bauer CA, Sun GH, Rosenfeld RM, Chandrasekhar SS, Cunningham ER Jr, et al. Clinical Practice Guideline: Tinnitus. Otolaryngol Head Neck Surg. 2014; 151:2 Suppl. S1–S40.
19. Langguth B, Elgoyhen AB. Current pharmacological treatments for tinnitus. Expert Opin Pharmacother. 2012; 13:2495–2509.
Article
20. Hesser H, Weise C, Rief W, Andersson G. The effect of waiting: a meta-analysis of wait-list control groups in trials for tinnitus distress. J Psychosom Res. 2011; 70:378–384.
Article
21. Labus J, Breil J, Stutzer H, Michel O. Meta-analysis for the effect of medical therapy vs. placebo on recovery of idiopathic sudden hearing loss. Laryngoscope. 2010; 120:1863–1871.
Article
22. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, et al. American Academy of Otolaryngology-Head and Neck Surgery. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012; 146:3 Suppl. S1–35.
23. Shim HJ, Kim SK, Park CH, Lee SH, Yoon SW, Ki AR, et al. Hearing abilities at ultrahigh frequency in patients with tinnitus. Clin Exp Otorhinolaryngo. 2009; 2:169–174.
Article
24. Fabijańska A, Smurzyński J, Hatzopoulos S, Kochanek K, Bartnik G, Raj-Koziak D, et al. The relationship between distortion product otoacoustic emissions and extended high-frequency audiometry in tinnitus patients. Part 1: normally hearing patients with unilateral tinnitus. Med Sci Monit. 2012; 18:CR765–CR770.
Article
25. Gouveris H, Maurer J, Mann W. DPOAEgrams in patients with acute tonal tinnitus. Otolaryngol Head Neck Surg. 2005; 132:550–553.
Article
26. Job A, Raynal M, Kossowski M. Susceptibility to tinnitus revealed at 2 kHz range by bilateral lower DPOAEs in normal hearing subjects with noise exposure. Audiol Neurootol. 2007; 12:137–144.
Article
27. Ami M, Abdullah A, Awang MA, Liyab B, Saim L. Relation of distortion product otoacoustic emission with tinnitus. Laryngoscope. 2008; 118:712–717.
Article
28. Kujawa SG, Liberman MC. Adding Insult to Injury: cochlear nerve degeneration after "temporary" noise-induced hearing loss. J Neurosci. 2009; 29:14077–14085.
Article
29. Schaette R, McAlpine D. Tinnitus with a normal audiogram: physiological evidence for hidden hearing loss and computational model. J Neurosci. 2011; 31:13452–13457.
Article
30. Piccirillo JF, Finnell J, Vlahiotis A, Chole RA, Spitznagel E Jr. Relief of idiopathic subjective tinnitus: is gabapentin effective. Arch Otolaryngol Head Neck Surg. 2007; 133:390–397.
31. Dobie RA, Sakai CS, Sullivan MD, Katon WJ, Russo J. Antidepressant treatment of tinnitus patients: report of a randomized clinical trial and clinical prediction of benefit. Am J Otol. 1993; 14:18–23.
32. Hamid M, Trune D. Issues, indications, and controversies regarding intratympanic steroid perfusion. Curr Opin Otolaryngol Head Neck Surg. 2008; 16:434–440.
Article
33. Pitovski DZ, Drescher MJ, Kerr TP, Drescher DG. Aldosterone mediates an increase in [3H] ouabain binding at Na+, K+-ATPase sites in the mammalian inner ear. Brain Res. 1993; 601:273–278.
Article
34. Hargunani CA, Kempton JB, DeGagne JM, Trune DR. Intratympanic injection of Dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol. 2006; 27:564–569.
35. Rask-Andersen H, Schrott-Fischer A, Pfaller K, Glueckert R. Perilymph/modiolar communication routes in the human cochlea. Ear Hear. 2006; 27:457–465.
Article
36. Banerjee A, Parnes LS. The biology of intratympanic drug administration and pharmacodynamics of round window drug absorption. Otolaryngol Clin North Am. 2004; 37:1035–1051.
Article
37. Juhn SK, Hamaguchi Y, Goycoolea M. Review of round window membrane permeability. Acta Otolaryngol Suppl. 1989; 457:43–48.
Article
38. Goycoolea MV, Carpenter AM, Muchow D. Ultrastructural study of the round-window membrane of the cat. Arch Otolaryngol Head Neck Surg. 1987; 113:617–624.
39. Alzamil KS, Linthicum FH Jr. Extraneous round window membranes and plugs: possible effect on intratympanic therapy. Ann Otol Rhinol Laryngol. 2000; 109:30–32.
Article
40. Silverstein H, Rowan PT, Olds MJ, Rosenberg SI. Inner ear perfusion and the role of round window patency. Am J Otol. 1997; 18:586–589.
41. An YH, Yu KK, Kwak MY, Yoon SW, Shim HJ. Prognostic Factors for the Outcomes of Intratympanic Dexamethasone in the Treatment of Acute Subjective Tinnitus. Otol Neurotol. 2014; 35:1330–1337.
Article
42. Nordang L, Linder B, Anniko M. Morphologic changes in round window membrane after topical hydrocortisone and dexamethasone treatment. Otol Neurotol. 2003; 24:339–343.
Article
43. Doyle KJ, Bauch C, Battista R, Beatty C, Hughes GB, Mason J, et al. Intratympanic steroid treatment: a review. Otol Neurotol. 2004; 25:1034–1039.
Article
Full Text Links
  • HMR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr